Ginkgo Bioworks Holdings, Inc.
DNA Real Time Price USDRecent trades of DNA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by DNA's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$10,000 Jun 18, 2025 Issue: Agriculture
-
$60,000 Apr 16, 2025 Issue: Budget/Appropriations Defense Medical/Disease Research/Clinical Labs
-
$70,000 Jan 20, 2025 Issue: Budget/Appropriations Defense Medical/Disease Research/Clinical Labs
-
$90,000 Oct 21, 2024 Issue: Medical/Disease Research/Clinical Labs Defense Budget/Appropriations
-
$90,000 Jul 22, 2024 Issue: Medical/Disease Research/Clinical Labs Defense Budget/Appropriations
-
$30,000 Jul 14, 2024 Issue: Agriculture
-
$90,000 Apr 21, 2024 Issue: Medical/Disease Research/Clinical Labs Defense Budget/Appropriations
-
$30,000 Apr 13, 2024 Issue: Agriculture
-
$10,000 Jan 22, 2024 Issue: Foreign Relations
-
$20,000 Oct 20, 2023 Issue: Foreign Relations
-
$30,000 Oct 18, 2023 Issue: Health Issues Defense
-
$90,000 Oct 16, 2023 Issue: Medical/Disease Research/Clinical Labs Defense Budget/Appropriations
-
$20,000 Jul 20, 2023 Issue: Foreign Relations
-
$90,000 Jul 16, 2023 Issue: Medical/Disease Research/Clinical Labs Defense Budget/Appropriations
-
$40,000 Jul 16, 2023 Issue: Agriculture Defense Science/Technology Health Issues
-
$30,000 Jul 12, 2023 Issue: Health Issues Defense
-
$10,000 Jan 20, 2023 Issue: Science/Technology Natural Resources Medical/Disease Research/Clinical Labs Defense
-
$80,000 Jan 15, 2023 Issue: Agriculture Defense Science/Technology Health Issues
-
$80,000 Oct 17, 2022 Issue: Agriculture Defense Education Science/Technology Health Issues
-
$10,000 Oct 17, 2022 Issue: Science/Technology Natural Resources Medical/Disease Research/Clinical Labs Defense
-
$10,000 Oct 17, 2022 Issue: Science/Technology Natural Resources Medical/Disease Research/Clinical Labs Defense
-
$80,000 Jul 16, 2022 Issue: Agriculture Defense Education Science/Technology Health Issues
-
$10,000 Jun 06, 2022 Issue: Defense Medical/Disease Research/Clinical Labs Natural Resources Science/Technology
-
$80,000 Apr 15, 2022 Issue: Health Issues Science/Technology Education Defense
-
$10,000 Jan 19, 2022 Issue: Defense Medical/Disease Research/Clinical Labs Science/Technology Natural Resources
-
$80,000 Jan 17, 2022 Issue: Health Issues Education Science/Technology Defense
-
$10,000 Oct 25, 2021 Issue: Science/Technology Natural Resources Medical/Disease Research/Clinical Labs Defense
-
$80,000 Oct 17, 2021 Issue: Health Issues Defense Education Science/Technology
-
$10,000 Jul 20, 2021 Issue: Medical/Disease Research/Clinical Labs Defense Science/Technology Natural Resources
-
$10,000 Jul 20, 2021 Issue: Medical/Disease Research/Clinical Labs Defense Science/Technology Natural Resources
-
$80,000 Jul 17, 2021 Issue: Education Health Issues Defense Science/Technology
-
$80,000 Apr 19, 2021 Issue: Education Defense Health Issues Science/Technology
-
$10,000 Feb 04, 2021 Issue: Defense Medical/Disease Research/Clinical Labs Science/Technology Natural Resources
-
$80,000 Jan 20, 2021 Issue: Budget/Appropriations Science/Technology Health Issues
-
$10,000 Dec 11, 2020 Issue: Natural Resources Science/Technology Medical/Disease Research/Clinical Labs Defense
-
$80,000 Oct 19, 2020 Issue: Science/Technology Health Issues Budget/Appropriations
-
$10,000 Aug 25, 2020 Issue: Natural Resources Science/Technology Defense Medical/Disease Research/Clinical Labs
-
$80,000 Jul 19, 2020 Issue: Health Issues Science/Technology
-
$10,000 May 11, 2020 Issue: Medical/Disease Research/Clinical Labs Defense Science/Technology Natural Resources
-
$40,000 Apr 20, 2020 Issue: Health Issues Science/Technology
-
$10,000 Mar 02, 2020 Issue: Natural Resources Science/Technology Defense Medical/Disease Research/Clinical Labs
-
$10,000 Oct 20, 2019 Issue: Natural Resources Science/Technology Medical/Disease Research/Clinical Labs Defense
Estimated quarterly lobbying spending
DNA Revenue by Segment or Geography
New patents grants
-
Patent Title: Compositions and methods for controlling plant pests and improving plant health Mar. 04, 2025
-
Patent Title: Biosynthesis of mogrosides Feb. 25, 2025
-
Patent Title: Virus vectors for targeting ophthalmic tissues Oct. 15, 2024
-
Patent Title: Antibody-evading virus vectors Sep. 17, 2024
-
Patent Title: Chimeric terpene synthases Sep. 03, 2024
-
Patent Title: Antibody-evading virus vectors Aug. 13, 2024
-
Patent Title: Recombinant adeno-associated virus vectors May. 14, 2024
-
Patent Title: Antibody-evading virus vectors May. 07, 2024
-
Patent Title: Adeno-associated viral vectors for treatment of niemann-pick disease type-c Feb. 20, 2024
-
Patent Title: Chemoautotrophic cells comprising an engineered carbon fixation pathway Jul. 11, 2023
-
Patent Title: Selective advantage in fermentation Jun. 13, 2023
-
Patent Title: Oleic acid production in yeast Apr. 25, 2023
-
Patent Title: Methods and compositions involving promoters derived from yarrowia lipolytica Feb. 07, 2023
-
Patent Title: Microorganisms engineered to use unconventional sources of phosphorous or sulfur Dec. 27, 2022
-
Patent Title: Increasing lipid production in oleaginous yeast Nov. 08, 2022
-
Patent Title: Compositions and methods for the production of compounds Oct. 25, 2022
-
Patent Title: Methods and systems for methylotrophic production of organic compounds Oct. 25, 2022
-
Patent Title: Compositions and methods for the production of compounds Sep. 20, 2022
-
Patent Title: Protective enzymes Jun. 14, 2022
-
Patent Title: Diacylglycerol acyltransferase (dga1) polynucleotides, and methods of increasing yeast cell lipid production by overexpression of heterologous dga1 Jun. 07, 2022
-
Patent Title: Biosynthesis of cannabinoids and cannabinoid precursors Mar. 15, 2022
-
Patent Title: Heterologous production of 10-methylstearic acid by cells expressing recombinant methyltransferase Feb. 01, 2022
-
Patent Title: Microorganisms engineered to use unconventional sources of nitrogen Jun. 22, 2021
-
Patent Title: Heterologous production of 10-methylstearic acid Apr. 13, 2021
-
Patent Title: Compositions and methods for the production of compounds Feb. 02, 2021
-
Patent Title: Methods for making chemoautotrophic cells by engineering an energy conversion pathway and a carbon fixation pathway Oct. 13, 2020
-
Patent Title: Methods and systems for cell state quantification Nov. 06, 2018
-
Patent Title: Methods and systems for chemoautotrophic production of organic compounds Feb. 27, 2018
-
Patent Title: Methods for preparative in vitro cloning Sep. 05, 2017
-
Patent Title: Methods and systems for cell state quantification Nov. 29, 2016
-
Patent Title: Methods and systems for chemoautotrophic production of organic compounds Jan. 08, 2013
Federal grants, loans, and purchases
- $53,725,683 2025-01-17 00:00:00 Agency: Department of Health and Human Services
- $449,762 2025-01-15 00:00:00 Agency: Department of Health and Human Services
- $1,236,102 2024-09-06 00:00:00 Agency: Department of Health and Human Services
- $0 2024-09-06 00:00:00 Agency: Department of Health and Human Services
- $54,509,851 2024-08-26 00:00:00 Agency: Department of Health and Human Services
- $15,979,933 2022-08-16 00:00:00 Agency: DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
Estimated quarterly amount awarded from public contracts
Recent insights relating to DNA
Recent picks made for DNA stock on CNBC
ETFs with the largest estimated holdings in DNA
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $DNA stock a Buy, Sell, or Hold?
- What is the price target for $DNA stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $DNA stock?
- Who owns the most shares of $DNA stock?
- What funds own $DNA stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view DNA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.